Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$98.3M
119M shares
52-week range
$0.73 – $1.51
9% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
www.oncolyticsbiotech.comNo one on the platform currently holds ONCY.
No tracked institution reports a position in ONCY as of their last filing.
No one on the platform has traded ONCY yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ONCY positive thoughts everyone, we need something in the next 2 weeks to get this going again!
View on StockTwits ↗$ONCY my bet is that the investors get fuked over here... massive dilution and reverse split likely ahead... I have no confidence in Jared... his move to Nevada was strategic.
View on StockTwits ↗$ONCY https://finance.yahoo.com/community/post/f5616109-1197-4045-a650-a5c6074bf7ce/
View on StockTwits ↗$ONCY https://finance.yahoo.com/community/post/1c4a8dc1-9788-4c49-9f44-59bb2e0d85e6/
View on StockTwits ↗$ONCY It’s all very nice, but they’ve run out of money, so it’s either a minimal buyout or heavy dilution. I don’t think there are any other options.
View on StockTwits ↗$ONCY very peaceful on the board without someone posting 25-45 billion times each day. Now just waiting for the news.
View on StockTwits ↗$ONCY the position oncy is in—<1$, cash runway measured in quarters not years, moderate short interest, and 100m+ OS—is not unique at all in the biotech space. Getting above 1$ and sustaining it based on a major de risking event like a type D meeting to align on a streamlined path to registration is also not unique.
View on StockTwits ↗$ONCY I find it unusual that there was no PR this morning about the Q2 release. They would never miss that PR????????? The D meeting must have be today!!
View on StockTwits ↗$ONCY this could be awesome if partnersip is announced which we need bad!! Latest established short interest ~7.95M shares Roughly 6.2% of today's 127.5M outstanding
View on StockTwits ↗$ONCY Metric Current best figure Comment Outstanding shares 127,510,505 Confirmed as of Aug. 10 in the new filing Fully diluted — acquisition case ~161.6M Assumes outstanding options, warrants, RSUs and acquisition-triggered awards participate Insider ownership ~2.4M common shares / ~2% No new open-market insider sales showing; compensation awards/options are separate Options ~22.10M 20.20M regular + 1.90M performance options Warrants ~8.20M Mostly $2.81 strike, plus ~537K at $2.25 RSUs ~470K Additional potential dilution Acquisition-triggered inducement awards ~3.29M Particularly relevant to our buyout calculations Institutional ownership Still incomplete for Q2 June 30 13Fs are continuing to arrive; I wouldn't lock in a final percentage yet Latest established short interest ~7.95M shares Roughly 6.2% of today's 127.5M outstanding
View on StockTwits ↗$ONCY sick and tired of being sick and tired hearing about collaborations and working on partnership...how many fucking times have we heard that with Matt and now Jared??? Just get er done like NOW!!! Or we will never see a dollar again.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1M | +3.2% | $-0.35 | $-0.39–$-0.32 | — | 4 |
| 2027 | $594629 | -49.9% | $-0.29 | $-0.35–$-0.23 | — | 4 |
| 2028 | $13M | +2031.7% | $-0.22 | $-0.36–$-0.02 | — | 5 |
| 2029 | $73M | +474.9% | $0.02 | $0.02–$0.02 | 45.7× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | $-0.05 | $-0.08 | -48.7% |
| 2026-05-14 | $-0.05 | $-0.08 | -60.0% |
| 2026-03-30 | $-0.06 | $-0.08 | -33.3% |
| 2025-11-12 | $-0.12 | $-0.10 | +16.7% |
| 2025-08-08 | $-0.11 | $-0.05 | +54.5% |
| 2025-05-14 | $-0.09 | $-0.06 | +33.3% |
| 2025-03-07 | $-0.08 | $-0.07 | +12.5% |
| 2024-11-12 | $-0.08 |
| $-0.09 |
| -12.5% |
| $594M |
| — |
| MGNXMacroGenics, Inc. | $4.08 | +1.49% | $259M | — |
| SRZNSurrozen, Inc. | $23.73 | -1.90% | $177M | — |
Source: Financial Modeling Prep · peers by sector/industry